Rigerna is a combination of "Rigel" and "RNA". Rigel is one of the brightest stars in the sky. By naming our company Rigerna, we aspire to achieve remarkable milestones in RNAi field.
Rigerna is an innovative siRNA biotech committed and dedicated to discovering drugs that benefit worldwide patients. Based on proprietary IP platform, our leading pipeline is on track to launch Phase II clinical trial for IgA nephropathy, ranking Top3 globally. In addition, Rigerna has also invented various extra-hepatic siRNA delivery platforms, including a novel kidney-targeting approach with PoC validation in NHP. With intial US$30m financing from reputable investors, we aim to become a game changer in the RNAi field in the future.